US › Healthcare

GRAIL, LLC (GRAL)

US · Healthcare · Diagnostics & Research

$72.70+3.46%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$40.8M
Revenue YoY
+28.1%
Net profit
$-93.2M
Profit YoY
+12.3%
EPS
$-1.37
EPS estimate
$-1.96
Net margin
-228.5%

EPS came in at -1.37 against a street estimate of -1.96 — a beat of 30.1%.

Key statistics

Market cap
$3.02B
Forward P/E
0.0
P/B
1.18
Book value
$60.79
EPS (TTM)
$-10.30
52-week high
$118.84
52-week low
$29.95
50-day MA
$66.80
200-day MA
$74.25
Beta
3.25

Analyst view

Analysts rate GRAIL, LLC a buy (1 buy, 3 hold, 0 sell out of 4) with an average price target of $70.12.

Shareholding

Insiders
5.23%
Institutions
83.53%

Largest institutional holders

FundStake
Baker Bros Advisors LP9.39%
Farallon Capital Management, L.L.C.7.58%
BlackRock Inc6.92%
Vanguard Group Inc4.62%
State Street Corp4.41%
PRIMECAP Management Company4.30%
Deep Track Capital, LP4.01%
Sessa Capital, L.P4.01%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for GRAIL, LLC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.